Central Artery
- 3E060 - Open
- 3E0600
- 3E06002 - Introduction Central Artery to High-dose Interleukin-2 with Antineoplastic, Open Approach
- 3E06003 - Introduction Central Artery to Low-dose Interleukin-2 with Antineoplastic, Open Approach
- 3E06005 - Introduction Central Artery to Other Antineoplastic with Antineoplastic, Open Approach
- 3E0600M - Introduction Central Artery to Monoclonal Antibody with Antineoplastic, Open Approach
- 3E0600P - Introduction Central Artery to Clofarabine with Antineoplastic, Open Approach
- 3E0601
- 3E06016 - Introduction Central Artery to Recombinant Human-activated Protein C with Thrombolytic, Open Approach
- 3E06017 - Introduction Central Artery to Other Thrombolytic with Thrombolytic, Open Approach
- 3E0602
- 3E06028 - Introduction Central Artery to Oxazolidinones with Anti-infective, Open Approach
- 3E06029 - Introduction Central Artery to Other Anti-infective with Anti-infective, Open Approach
- 3E0603
- 3E0603Z - Introduction Central Artery to No Qualifier with Anti-inflammatory, Open Approach
- 3E0604
- 3E0604Z - Introduction Central Artery to No Qualifier with Serum, Toxoid and Vaccine, Open Approach
- 3E0606
- 3E0606Z - Introduction Central Artery to No Qualifier with Nutritional Substance, Open Approach
- 3E0607
- 3E0607Z - Introduction Central Artery to No Qualifier with Electrolytic and Water Balance Substance, Open Approach
- 3E060F
- 3E060FZ - Introduction Central Artery to No Qualifier with Intracirculatory Anesthetic, Open Approach
- 3E060G
- 3E060GC - Introduction Central Artery to Other Substance with Other Therapeutic Substance, Open Approach
- 3E060GN - Introduction Central Artery to Blood Brain Barrier Disruption with Other Therapeutic Substance, Open Approach
- 3E060H
- 3E060HZ - Introduction Central Artery to No Qualifier with Radioactive Substance, Open Approach
- 3E060K
- 3E060KZ - Introduction Central Artery to No Qualifier with Other Diagnostic Substance, Open Approach
- 3E060N
- 3E060NZ - Introduction Central Artery to No Qualifier with Analgesics, Hypnotics, Sedatives, Open Approach
- 3E060P
- 3E060PZ - Introduction Central Artery to No Qualifier with Platelet Inhibitor, Open Approach
- 3E060R
- 3E060RZ - Introduction Central Artery to No Qualifier with Antiarrhythmic, Open Approach
- 3E060T
- 3E060TZ - Introduction Central Artery to No Qualifier with Destructive Agent, Open Approach
- 3E060V
- 3E060VG - Introduction Central Artery to Insulin with Hormone, Open Approach
- 3E060VH - Introduction Central Artery to Human B-type Natriuretic Peptide with Hormone, Open Approach
- 3E060VJ - Introduction Central Artery to Other Hormone with Hormone, Open Approach
- 3E060W
- 3E060WK - Introduction Central Artery to Immunostimulator with Immunotherapeutic, Open Approach
- 3E060WL - Introduction Central Artery to Immunosuppressive with Immunotherapeutic, Open Approach
- 3E060X
- 3E060XZ - Introduction Central Artery to No Qualifier with Vasopressor, Open Approach
- 3E063 - Percutaneous
- 3E0630
- 3E06302 - Introduction Central Artery to High-dose Interleukin-2 with Antineoplastic, Percutaneous Approach
- 3E06303 - Introduction Central Artery to Low-dose Interleukin-2 with Antineoplastic, Percutaneous Approach
- 3E06305 - Introduction Central Artery to Other Antineoplastic with Antineoplastic, Percutaneous Approach
- 3E0630M - Introduction Central Artery to Monoclonal Antibody with Antineoplastic, Percutaneous Approach
- 3E0630P - Introduction Central Artery to Clofarabine with Antineoplastic, Percutaneous Approach
- 3E0631
- 3E06316 - Introduction Central Artery to Recombinant Human-activated Protein C with Thrombolytic, Percutaneous Approach
- 3E06317 - Introduction Central Artery to Other Thrombolytic with Thrombolytic, Percutaneous Approach
- 3E0632
- 3E06328 - Introduction Central Artery to Oxazolidinones with Anti-infective, Percutaneous Approach
- 3E06329 - Introduction Central Artery to Other Anti-infective with Anti-infective, Percutaneous Approach
- 3E0633
- 3E0633Z - Introduction Central Artery to No Qualifier with Anti-inflammatory, Percutaneous Approach
- 3E0634
- 3E0634Z - Introduction Central Artery to No Qualifier with Serum, Toxoid and Vaccine, Percutaneous Approach
- 3E0636
- 3E0636Z - Introduction Central Artery to No Qualifier with Nutritional Substance, Percutaneous Approach
- 3E0637
- 3E0637Z - Introduction Central Artery to No Qualifier with Electrolytic and Water Balance Substance, Percutaneous Approach
- 3E063F
- 3E063FZ - Introduction Central Artery to No Qualifier with Intracirculatory Anesthetic, Percutaneous Approach
- 3E063G
- 3E063GC - Introduction Central Artery to Other Substance with Other Therapeutic Substance, Percutaneous Approach
- 3E063GN - Introduction Central Artery to Blood Brain Barrier Disruption with Other Therapeutic Substance, Percutaneous Approach
- 3E063H
- 3E063HZ - Introduction Central Artery to No Qualifier with Radioactive Substance, Percutaneous Approach
- 3E063K
- 3E063KZ - Introduction Central Artery to No Qualifier with Other Diagnostic Substance, Percutaneous Approach
- 3E063N
- 3E063NZ - Introduction Central Artery to No Qualifier with Analgesics, Hypnotics, Sedatives, Percutaneous Approach
- 3E063P
- 3E063PZ - Introduction Central Artery to No Qualifier with Platelet Inhibitor, Percutaneous Approach
- 3E063R
- 3E063RZ - Introduction Central Artery to No Qualifier with Antiarrhythmic, Percutaneous Approach
- 3E063T
- 3E063TZ - Introduction Central Artery to No Qualifier with Destructive Agent, Percutaneous Approach
- 3E063V
- 3E063VG - Introduction Central Artery to Insulin with Hormone, Percutaneous Approach
- 3E063VH - Introduction Central Artery to Human B-type Natriuretic Peptide with Hormone, Percutaneous Approach
- 3E063VJ - Introduction Central Artery to Other Hormone with Hormone, Percutaneous Approach
- 3E063W
- 3E063WK - Introduction Central Artery to Immunostimulator with Immunotherapeutic, Percutaneous Approach
- 3E063WL - Introduction Central Artery to Immunosuppressive with Immunotherapeutic, Percutaneous Approach
- 3E063X
- 3E063XZ - Introduction Central Artery to No Qualifier with Vasopressor, Percutaneous Approach